A new red flag for non‐relapse mortality: Prolonged transfusion dependence in acute myeloid leukemia allogeneic hematopoietic cell transplant recipients
Vox Sanguinis · 16.11.2026
DOI: 10.1111/vox.70417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 16.11.2026. Verfasst von Shan Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives The hematopoietic cell transplantation comorbidity index (HCT‐CI) is widely used to evaluate non‐relapse mortality (NRM) risks after HCT. We aimed to evaluate whether the lack of transfusion independence (TI) by Day 30 predicted increased NRM independently of HCT‐CI in acute myeloid leukemia (AML) allogeneic (allo‐) HCT recipients. Materials and Methods The relationships between HCT ‐ CI , TI, and NRM were evaluated using multivariate analyses in this single‐center retrospective study.
Results
A total of 676 AML allo‐HCT recipients were evaluated, including 234 (35%) with HCT‐CI score ≥3. Median follow‐up among survivors ( n = 307) was 7.1 years (range: 2.7–11.8). High (≥3) HCT‐CI score was significantly associated with increased NRM at 2 years but showed no correlation with attainment of red blood cell (RBC) or platelet (PLT) TI by Day 30. However, the lack of RBC or PLT TI by Day 30 predicted higher NRM independently of HCT‐CI. The 2‐year NRM incidences were 0.297 (95% confidence interval [CI]: 0.246–0.350) versus 0.137 (95% CI: 0.105–0.174) for those without or with RBC TI, with adjusted hazard ratio (aHR) of 2.02 (95% CI: 1.44–2.84, p < 0.001). For those without and with PLT TI, the NRM incidences were 0.374 (95% CI: 0.276–0.471) and 0.179 (95% CI: 0.149–0.212), with aHR of 2.07 (95% CI: 1.30–3.29, p = 0.002). Patients with both high HCT‐CI scores and lack of TI by Day 30 had the highest NRM incidence.
Conclusion
Lack of TI by Day 30 is an early post‐HCT warning sign which predicted increased 2‐year NRM independently of HCT‐CI and can be combined with HCT‐CI to further stratify NRM risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
- Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
- Division of Molecular Pathology & Therapy Biomarkers, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
ORCID-Profile: Shan Yuan, Dongyun Yang, Ryotaro Nakamura, Monzr M Al Malki, Amandeep Salhotra, Michelle Afkhami
Zitieren
APA
Yuan, S., Yang, D., Nakamura, R., Malki, M. M. A., Salhotra, A., Afkhami, M., & Wang, S. (2026). A new red flag for non‐relapse mortality: Prolonged transfusion dependence in acute myeloid leukemia allogeneic hematopoietic cell transplant recipients. Vox Sanguinis. https://doi.org/10.1111/vox.70417
Vancouver
Yuan S, Yang D, Nakamura R, Malki MMA, Salhotra A, Afkhami M, et al. A new red flag for non‐relapse mortality: Prolonged transfusion dependence in acute myeloid leukemia allogeneic hematopoietic cell transplant recipients. Vox Sanguinis. 2026. doi:10.1111/vox.70417
BibTeX
@article{Yuan2026,
author = {Yuan, Shan and Yang, Dongyun and Nakamura, Ryotaro and Malki, Monzr M Al and Salhotra, Amandeep and Afkhami, Michelle and Wang, Shirong},
title = {A new red flag for non‐relapse mortality: Prolonged transfusion dependence in acute myeloid leukemia allogeneic hematopoietic cell transplant recipients},
journal = {Vox Sanguinis},
year = {2026},
doi = {10.1111/vox.70417}
}
EUVIMED